Literature DB >> 11775436

Biology of liver metastases.

R S Berman1, C A Portera, L M Ellis.   

Abstract

A primary goal of cancer research is an increased understanding of the molecular mechanisms mediating the process of cancer metastasis. Analyses of colon cancer cells (the seeds) and the microenvironment (the soil) have increased our understanding of the biologic mechanisms mediating metastasis formation. Insight into the molecular mechanisms regulating the pathobiology of colon cancer metastasis, as well as a better understanding of the interaction between the metastatic cell and the host environment (including the vasculature), should provide a foundation for new therapeutic approaches. To the clinician, it is readily apparent that by the time metastases form, most steps in the metastatic cascade have completed. Therefore, therapy to down-regulate or interrupt the last stages of metastasis, proliferation and angiogenesis as well as mechanisms to disrupt cell survival signals seems the most promising areas of investigation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11775436     DOI: 10.1007/978-1-4757-3371-6_10

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  4 in total

1.  Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers.

Authors:  Matthias P A Ebert; Suzanne H Mooney; Lori Tonnes-Priddy; Joe Lograsso; Juliane Hoffmann; Jie Chen; Christoph Röcken; Hans-Ulrich Schulz; Peter Malfertheiner; Catherine Lofton-Day
Journal:  Neoplasia       Date:  2005-08       Impact factor: 5.715

2.  Sp1 regulates osteopontin expression in SW480 human colon adenocarcinoma cells.

Authors:  Yoji Takami; Michael B Russell; Chengjiang Gao; Zhiyong Mi; Hongtao Guo; Christopher R Mantyh; Paul C Kuo
Journal:  Surgery       Date:  2007-08       Impact factor: 3.982

3.  Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy.

Authors:  J De Castro; J L González-Larriba; S Vázquez; B Massutí; J M Sanchez-Torres; M Dómine; P Garrido; A Calles; A Artal; R Collado; R García; M Sereno; M Majem; J A Macías; O Juan; J Gómez-Codina; B Hernández; M Lázaro; A L Ortega; M Cobo; J M Trigo; E Carcereny; C Rolfo; S Macia; J Muñoz; P Diz; M Méndez; F Rosillo; L Paz-Ares; J V Cardona; D Isla
Journal:  Clin Transl Oncol       Date:  2016-07-01       Impact factor: 3.405

4.  Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro.

Authors:  Andreas Seeber; Agnieszka Martowicz; Gilbert Spizzo; Thomas Buratti; Peter Obrist; Dominic Fong; Guenther Gastl; Gerold Untergasser
Journal:  BMC Cancer       Date:  2015-05-07       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.